Pharma in Focus

News Posted 3 July 2026 PM A spate of ANZ leadership departures has left a surprising number of top operators ripe for the picking, making news that six country leaders were now between jobs, our top story this week. Some of industry's biggest names have exited their high-profile positions - including two in a 24 hour period last week - leaving a total of five companies without named leaders and six leaders out of work.

News Posted 3 July 2026 PM Australian family-owned pharmaceutical manufacturer Vitex Pharmaceuticals has officially opened its $250 million plant called Wonderland, tripling the company’s production footprint. Located in Eastern Creek, Western Sydney, Wonderland, which marks the most significant investment in Australian pharmaceutical manufacturing in more than two decades, strengthens Australia’s sovereign capability and secures critical domestic medicine supply.

News Posted 3 July 2026 AM Pharmaceutical companies felt the pinch from pricing pressures last year, which showed in an eight per cent drop in financial support for patient organisations in 2025 compared to 2024, but they still helped with over $9.4 million. Medicines Australia released its Patient Organisation Support Reports as part of its transparency reporting.

News Posted 3 July 2026 AM Last week the TGA approved Sanofi’s pegged blockbuster Altuviiio, adding to a growing list of haemophilia A treatment options in Australia, with the French pharma “working with urgency” to ensure equitable access, according to ANZ Country Lead and Head of Pharma, Liz Selby. “The registration of Altuviiio marks an exciting milestone for the haemophilia community in Australia.

News Posted 3 July 2026 AM Patients are missing out on a “gamechanger” cancer treatment because health systems can’t accurately assess its cost-effectiveness, a study has found. Researchers from the University of Queensland set out to review the value for money of theranostic nuclear medicine, which combines diagnostic imaging and targeted radiopharmaceutical therapy to deliver precise, personalised cancer care with generally low toxicity. To see the whole article, please login

News Posted 2 July 2026 PM The European Commission has opened a formal antitrust investigation into claims that Sanofi disparaged CSL’s flu vaccine Fluad. Sanofi allegedly ran a misleading communication campaign that portrayed Fluad as inferior to Sanofi’s Efluelda (branded as Fluzone High-Dose in Australia), contravening national vaccination recommendations in several EU member states. To see the whole article, please login

News Posted 2 July 2026 AM The TGA is seeking stakeholder's feedback on the regulation of radiopharmaceuticals in Australia, with interested parties given until the end of this month to make a submission. The consultation is intended to discern stakeholder's actual experiences with existing regulatory pathways, exemptions, and access mechanisms concerning the new type of treatments.

News Posted 2 July 2026 AM A closed-door industry event for pharma and life science leaders in Sydney last night named commercial outsourcing as an emerging strategic growth lever for the sector. DKSH Australia hosted the event and unveiled new research which showed 90 per cent of industry executives already outsourced some part of their business while more than 60 per cent had increased outsourcing in the past three years. To see the whole article, please login

News Posted 2 July 2026 AM Three Eli Lilly drugs are forecast to make up nearly half of the total sales of the world’s top 10 best-selling drugs in 2032, with diabetes drug Mounjaro topping the list at US$45.5 billion.

News Posted 2 July 2026 AM The backlash to AstraZeneca's decision to remove the monthly 3.6mg dose of GnRH agonist Zoladex from the PBS is not blowing over, despite assurances from the pharma that it will continue supply for those women who need it.